DDInter40 DDInter927
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Alefacept {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bleomycin
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ibritumomab tiuxetan
Alefacept {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Alefacept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Bleomycin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ibritumomab tiuxetan
Alefacept may lead to a major life threatening interaction when taken with Upadacitinib